title: Vigabatrin: a novel therapy for seizure disorders.
abstract: OBJECTIVE
  To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of vigabatrin and its role in the management of seizure disorders.
  
  
  METHODS
  A MEDLINE search of English-language literature from January 1993 through January 1999 was conducted using vigabatrin as a search term to identify pertinent studies and review articles. Additional studies were identified from the bibliographies of reviewed literature. The manufacturer provided postmarketing surveillance data. Priority was given to randomized, double-blind, placebo-controlled studies.
  
  
  RESULTS
  Vigabatrin is a selective and irreversible inhibitor of gamma-aminobutyric acid transaminase. In controlled clinical trials of vigabatrin add-on therapy in patients with uncontrolled partial seizures, 24-67% of patients achieved a < or =50% reduction in seizure frequency. Data from two comparative trials with carbamazepine monotherapy indicate that vigabatrin monotherapy reduces the frequency of partial seizures in patients with newly diagnosed epilepsy. Vigabatrin also controls infantile spasms, particularly those associated with tuberous sclerosis. Vigabatrin is more effective in patients with partial seizures than in those with generalized seizures. The drug is generally well tolerated. Headache and drowsiness were the most common adverse effects observed in controlled clinical trials; visual field defects, psychiatric reactions, and hyperactivity also have been reported. There are no known clinically significant drug interactions.
  
  
  CONCLUSIONS
  Vigabatrin improves seizure control as add-on therapy for refractory partial seizures and may produce therapeutic benefits in the treatment of infantile spasms. Vigabatrin is generally well tolerated, with a convenient administration schedule, a lack of known significant drug interactions, and no need for routine monitoring of plasma concentrations.
authors.affiliation: School of Pharmacy and Department of Neurology, University of Wisconsin, Madison 53706, USA. BEGIDAL@pharmacy.wisc.edu
authors.forename: B E
authors.initials: BE
authors.lastname: Gidal
authors.forename: M D
authors.initials: MD
authors.lastname: Privitera
authors.forename: R D
authors.initials: RD
authors.lastname: Sheth
authors.forename: J T
authors.initials: JT
authors.lastname: Gilman
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D012640:Seizures / Q000188:drug therapy* / Q000191:economics; D020888:Vigabatrin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D020888:Vigabatrin